Rigel Pharmaceuticals Company Profile (NASDAQ:RIGL)

About Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals logoRigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company's clinical programs include clinical studies of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor in a range of indications. It has completed Phase III clinical trial of fostamatinib in chronic immune thrombocytopenia (ITP). The Company is conducting a Phase II clinical study with fostamatinib in autoimmune hemolytic anemia (AIHA) and a Phase II clinical study for IgA nephropathy (IgAN). In addition, the Company has two oncology product candidates under development. The Company's product pipeline also includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor indicated for patients with ocular graft-versus-host disease (GvHD). R348 reduces inflammation and limits the damage to the eye tissue caused by the disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:RIGL
  • CUSIP: 76655960
  • Web: www.rigel.com
Capitalization:
  • Market Cap: $303.64 million
  • Outstanding Shares: 122,434,000
Average Prices:
  • 50 Day Moving Avg: $2.86
  • 200 Day Moving Avg: $2.66
  • 52 Week Range: $1.94 - $4.38
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.05
  • P/E Growth: -0.07
Sales & Book Value:
  • Annual Revenue: $18.94 million
  • Price / Sales: 16.03
  • Book Value: $0.69 per share
  • Price / Book: 3.59
Profitability:
  • EBIDTA: ($61,860,000.00)
  • Net Margins: -255.84%
  • Return on Equity: -86.54%
  • Return on Assets: -61.98%
Debt:
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 4.19%
  • Quick Ratio: 4.19%
Misc:
  • Average Volume: 1.15 million shs.
  • Beta: 1.24
  • Short Ratio: 2.82
 

Frequently Asked Questions for Rigel Pharmaceuticals (NASDAQ:RIGL)

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its earnings results on Tuesday, May, 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The company earned $3.58 million during the quarter, compared to analysts' expectations of $4.30 million. Rigel Pharmaceuticals had a negative return on equity of 86.54% and a negative net margin of 255.84%. During the same quarter in the prior year, the business posted ($0.19) EPS. View Rigel Pharmaceuticals' Earnings History.

When will Rigel Pharmaceuticals make its next earnings announcement?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Rigel Pharmaceuticals.

Where is Rigel Pharmaceuticals' stock going? Where will Rigel Pharmaceuticals' stock price be in 2017?

5 brokers have issued 1 year price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Rigel Pharmaceuticals' stock price to reach $6.20 in the next year. View Analyst Ratings for Rigel Pharmaceuticals.

What are analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (5/10/2017)
  • 2. Jefferies Group LLC analysts commented, "RIGL is on track to submit an NDA for fosta in ITP in 1Q17; next major catalyst could be FDA acceptance by ~May given mixed Ph3 data & limited FDA interactions following Ph3 data. YE16 cash of ~$75M, plus net proceeds of $43M from recent offering, should be sufficient at least for next 12 months including pre-commercial activities, per RIGL. If fosta is approved in ITP, we see >50% upside to our current PT of $5." (3/8/2017)
  • 3. BMO Capital Markets analysts commented, "We remain focused on fostamatinib's pending NDA submission, which we believe supports approval given clear and consistent benefit in ITP, despite one pivotal trial missing statistical significance. We believe reaching an FDA Adcom would be a positive event, as a panel of clinicians would likely recommend approval. Additionally, we believe the fostamatinib addressable patient population is larger than the 18% stable response rate, as real world use would include patients who maintain platelet counts greater than 30K/ul, according to physician feedback. We rate RIGL shares Outperform." (3/8/2017)

Who are some of Rigel Pharmaceuticals' key competitors?

Who owns Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.99%), Wellington Management Group LLP (11.32%), Vanguard Group Inc. (4.65%), OppenheimerFunds Inc. (4.09%), Palo Alto Investors LLC (3.48%) and NEA Management Company LLC (2.65%). View Institutional Ownership Trends for Rigel Pharmaceuticals.

Who sold Rigel Pharmaceuticals stock? Who is selling Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Goldman Sachs Group Inc., Credit Suisse AG, Morgan Stanley, JPMorgan Chase & Co., Bank of America Corp DE, Dimensional Fund Advisors LP and Nationwide Fund Advisors. View Insider Buying and Selling for Rigel Pharmaceuticals.

Who bought Rigel Pharmaceuticals stock? Who is buying Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Wellington Management Group LLP, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc., Candriam Luxembourg S.C.A., Geode Capital Management LLC and Paulson & CO. Inc.. View Insider Buying and Selling for Rigel Pharmaceuticals.

How do I buy Rigel Pharmaceuticals stock?

Shares of Rigel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Rigel Pharmaceuticals stock cost?

One share of Rigel Pharmaceuticals stock can currently be purchased for approximately $2.48.

Analyst Ratings

Consensus Ratings for Rigel Pharmaceuticals (NASDAQ:RIGL) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.20 (150.00% upside)

Analysts' Ratings History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/3/2017HC WainwrightReiterated RatingBuy$6.00MediumView Rating Details
3/8/2017Jefferies Group LLCReiterated RatingBuy$5.00HighView Rating Details
3/8/2017BMO Capital MarketsReiterated RatingOutperform$4.00HighView Rating Details
11/2/2016Piper Jaffray CompaniesSet Price TargetBuy$11.00N/AView Rating Details
8/3/2016JPMorgan Chase & Co.Reiterated RatingBuy$5.00N/AView Rating Details
4/23/2016Credit Suisse Group AGUpgradeBuyN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Earnings by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Earnings History by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017        
5/2/2017Q1 2017($0.12)($0.13)$4.30 million$3.58 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.17)($0.16)$4.25 million$3.00 millionViewListenView Earnings Details
11/1/2016Q316($0.23)($0.24)$3.97 million$3.76 millionViewListenView Earnings Details
8/2/2016Q216($0.20)($0.15)$3.75 million$8.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.19)($0.19)$4.00 million$5.03 millionViewListenView Earnings Details
3/8/2016Q415($0.14)($0.14)$8.90 million$8.50 millionViewListenView Earnings Details
11/3/2015Q315($0.17)($0.08)$5.00 million$12.90 millionViewListenView Earnings Details
8/4/2015Q215($0.22)($0.16)$2.67 million$5.18 millionViewListenView Earnings Details
5/7/2015Q414($0.18)($0.21)$16.00 million$2.18 millionViewListenView Earnings Details
3/3/2015Q4($0.27)($0.25)$2.50 million$8.25 millionViewN/AView Earnings Details
11/4/2014Q314($0.27)($0.24)$1.70 millionViewN/AView Earnings Details
8/5/2014Q214($0.25)($0.29)$1.05 millionViewN/AView Earnings Details
5/7/2014Q114($0.25)($0.25)$0.43 millionViewN/AView Earnings Details
3/4/2014Q4 13($0.25)($0.19)$5.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.29)($0.27)$260.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.30)($0.26)$0.53 million$1.40 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.30)($0.29)$1.73 millionViewN/AView Earnings Details
3/5/2013Q4 2012($0.32)($0.30)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.36)$0.84 millionViewN/AView Earnings Details
8/7/2012($0.34)($0.35)ViewN/AView Earnings Details
5/1/2012($0.33)($0.32)ViewN/AView Earnings Details
3/6/2012($0.28)($0.36)ViewN/AView Earnings Details
11/1/2011($0.28)($0.25)ViewN/AView Earnings Details
8/2/2011($0.36)($0.37)ViewN/AView Earnings Details
5/3/2011($0.36)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rigel Pharmaceuticals (NASDAQ:RIGL)
2017 EPS Consensus Estimate: ($0.57)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.13)($0.13)($0.13)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Rigel Pharmaceuticals (NASDAQ:RIGL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Insider Ownership Percentage: 7.07%
Institutional Ownership Percentage: 72.23%
Insider Trades by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Insider Trades by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/30/2016Donald G PayanEVPSell5,303$4.00$21,212.00View SEC Filing  
4/1/2015Donald G PayanEVPSell10,000$3.75$37,500.00View SEC Filing  
12/18/2014Dolly VanceEVPSell1,000$2.22$2,220.00View SEC Filing  
9/3/2014Donald G PayanEVPSell20,000$2.56$51,200.00View SEC Filing  
11/19/2013Bvf Partners P/Ilmajor shareholderSell484,622$2.64$1,279,402.08View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy32,700$3.47$113,469.00View SEC Filing  
9/13/2012Dolly VanceEVPSell4,151$10.43$43,294.93View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Rigel Pharmaceuticals (NASDAQ:RIGL)
Latest Headlines for Rigel Pharmaceuticals (NASDAQ:RIGL)
Source:
DateHeadline
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 23 at 12:30 PM
finance.yahoo.com logoETFs with exposure to Rigel Pharmaceuticals, Inc. : May 16, 2017
finance.yahoo.com - May 16 at 7:24 PM
fool.com logo3 Biotech Stocks I'd Buy Right Now
www.fool.com - May 15 at 6:46 PM
americanbankingnews.com logo Analysts Expect Rigel Pharmaceuticals, Inc. (RIGL) Will Post Quarterly Sales of $3 Million
www.americanbankingnews.com - May 13 at 9:40 AM
americanbankingnews.com logoZacks: Analysts Expect Rigel Pharmaceuticals, Inc. (RIGL) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - May 11 at 8:22 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 7:24 AM
finance.yahoo.com logoETFs with exposure to Rigel Pharmaceuticals, Inc. : May 5, 2017
finance.yahoo.com - May 5 at 7:48 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) to Post FY2017 Earnings of ($0.58) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 5 at 1:22 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. to Post FY2021 Earnings of $0.13 Per Share, Jefferies Group Forecasts (RIGL)
www.americanbankingnews.com - May 4 at 8:38 PM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 4 at 7:46 PM
rttnews.com logoEARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q1 Earnings Report
www.rttnews.com - May 4 at 8:49 AM
seekingalpha.com logoRigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 3 at 7:25 PM
finance.yahoo.com logoEdited Transcript of RIGL earnings conference call or presentation 2-May-17 9:00pm GMT
finance.yahoo.com - May 3 at 7:25 PM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : May 3, 2017
finance.yahoo.com - May 3 at 7:25 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Posts Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 3 at 5:36 PM
americanbankingnews.com logoRigel Pharmaceuticals (RIGL) Earns Daily Media Impact Score of 0.28
www.americanbankingnews.com - May 3 at 1:03 AM
marketbeat.com logoRigel reports 1Q loss
marketbeat.com - May 2 at 6:38 PM
finance.yahoo.com logoRigel Announces First Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - May 2 at 5:22 PM
finance.yahoo.com logoInvestor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 9:48 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 2 at 7:30 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 30 at 8:30 PM
americanbankingnews.com logoRigel Pharmaceuticals (RIGL) Earns Media Impact Rating of 0.20
www.americanbankingnews.com - April 29 at 9:57 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 29 at 8:31 AM
prnewswire.com logoRigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States - PR Newswire (press release)
www.prnewswire.com - April 28 at 8:43 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 28 at 2:17 PM
prnewswire.com logoTechnical Reports on Generic Drugs Stocks -- Mylan, Allergan, Horizon Pharma, and Rigel Pharma - PR Newswire (press release)
www.prnewswire.com - April 27 at 10:59 AM
finance.yahoo.com logoRigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States
finance.yahoo.com - April 27 at 10:59 AM
finance.yahoo.com logoRigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results
finance.yahoo.com - April 25 at 10:10 AM
americanbankingnews.com logoRigel Pharmaceuticals (RIGL) Receives Daily News Sentiment Rating of -0.12
www.americanbankingnews.com - April 24 at 2:16 PM
seekingalpha.com logoWhy Rigel Pharmaceuticals Investors Should Come Back Later - Seeking Alpha
seekingalpha.com - April 21 at 8:32 AM
americanbankingnews.com logoSomewhat Positive News Coverage Extremely Likely to Impact Rigel Pharmaceuticals (RIGL) Share Price
www.americanbankingnews.com - April 20 at 7:22 PM
americanbankingnews.com logo Brokerages Anticipate Rigel Pharmaceuticals, Inc. (RIGL) Will Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - April 20 at 9:03 AM
finance.yahoo.com logoRigel Pharmaceuticals Files NDA for Thrombocytopenia Drug - Yahoo Finance
finance.yahoo.com - April 20 at 12:31 AM
rttnews.com logoOMED Disappoints, PBYI Soars, AMAG Seeks Expanded Approval For Makena
www.rttnews.com - April 19 at 9:34 AM
streetinsider.com logoRigel Pharma (RIGL) Submits NDA for Fostamatinib in Chronic ITP
www.streetinsider.com - April 18 at 9:28 AM
zacks.com logoRigel Pharmaceuticals Files NDA for Thrombocytopenia Drug
www.zacks.com - April 18 at 9:28 AM
finance.yahoo.com logoRigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
finance.yahoo.com - April 17 at 6:36 PM
americanbankingnews.com logoVery Positive Media Coverage Likely to Effect Rigel Pharmaceuticals (RIGL) Share Price
www.americanbankingnews.com - April 16 at 8:28 AM
seekingalpha.com logoRigel Pharmaceuticals Is Worth A Timely Look - Seeking Alpha
seekingalpha.com - March 28 at 7:22 PM
zacks.com logoIncreased Earnings Estimates Seen for Rigel (RIGL): Can It Move Higher?
www.zacks.com - March 27 at 9:27 AM
us.rd.yahoo.com logoWill Rigel Pharmaceuticals (RIGL) Continue to Surge Higher?
us.rd.yahoo.com - March 24 at 7:22 PM
fool.com logoAfter Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere?
www.fool.com - March 24 at 10:02 AM
finance.yahoo.com logoRIGEL PHARMACEUTICALS INC Financials
finance.yahoo.com - March 11 at 7:25 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 11 at 10:54 AM
finance.yahoo.com logoEdited Transcript of RIGL earnings conference call or presentation 7-Mar-17 10:00pm GMT
finance.yahoo.com - March 8 at 7:47 PM
rttnews.com logoEARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q4 Earnings Report
www.rttnews.com - March 7 at 7:24 PM
us.rd.yahoo.com logoRigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update
us.rd.yahoo.com - March 7 at 7:24 PM
biz.yahoo.com logoRIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
us.rd.yahoo.com - March 7 at 7:24 PM
biz.yahoo.com logoQ4 2016 Rigel Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 7 at 9:26 AM
biz.yahoo.com logoRigel Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
biz.yahoo.com - March 7 at 9:26 AM

Social

Chart

Rigel Pharmaceuticals (RIGL) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff